- High resolution 3D bio-printed soft tissue matrix mimics the patient’s anatomy and allows for ingrowth to facilitate healing and improved outcomes
- The unlimited supply of recombinant human collagen (rhCollagen) on a plant basis does not require animal or human sources for production
ROCK HILL, SC and REHOVOT, Israel, June 22, 2021 (GLOBE NEWSWIRE) – Today, 3D Systems (NYSE: DDD) and CollPlant Biotechnologies (NASDAQ: CLGN) announced that they have signed a joint development agreement for a 3D bio-printed regenerative have soft tissue matrix for use in breast reconstruction procedures in combination with an implant. The soft tissue matrix is designed to support the lower part of the breast while expanding the implant pocket and providing increased coverage of the implant. Using 3D bioprinting, these matrices can be designed to match the patient’s anatomy to support the breast implant.
According to the World Health Organization, 2.3 million women worldwide were diagnosed with breast cancer in 2020, the vast majority of which required partial or total removal of breast tissue. The probability of survival is 90% or greater due to highly effective treatments, which increases the focus on providing improved options for reconstruction. Most breast reconstruction procedures use soft tissue matrices obtained from human cadavers or animals. These sources have been linked to supply shortages and lot-to-lot variability, as well as the possibility of an immune response that affects healing.
Through this joint development agreement, 3D Systems and CollPlant – with combined expertise in 3D printing, healthcare, bioprinting and bio inks – will develop 3D bio-printed soft tissue matrices with rhCollagen. The 3D bio-printed soft tissue matrix product under development is designed to meet the required physical and mechanical properties while promoting cell infiltration and proliferation by using bioink formulations based on rhCollagen that promote tissue regeneration. The companies believe their efforts will result in tissue matrices that offer superior performance, consistency and safety due to their vegetable origin and identical consistency with natural human collagen that does not induce an adverse immune response in humans.
“In January of this year, we announced our intention to increase investment in regenerative medicine and focus on developing and commercializing solutions to transform health care and bring significant benefits to patients,” said Dr. Jeffrey Graves, President & Chief Executive Officer, 3D Systems. “With this project, which we are starting with CollPlant, we are investigating a novel application that could offer a new reconstruction treatment for breast cancer survivors. It’s inspiring to be involved in a project that has the potential to have such a positive impact on the human condition. “
“We have partnered with 3D Systems to offer a regenerative soft tissue matrix that can significantly expand the addressable market for soft tissue reinforcement in breast implants. A regenerative solution can increase safety, eliminate product variability and improve outcomes by promoting new tissue growth, ”said Yehiel Tal, CEO of CollPlant. “We are pleased to deepen our cooperation with 3D Systems as part of the CollPlant strategy as a leading company in regenerative medicine.”
About 3D systems
More than 30 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as a leader in AM solutions, it enables manufacturers to develop products and business models that have never been possible before through transformed workflows. It does this with the company’s industry-leading digital manufacturing ecosystem consisting of plastic and metal 3D printers, printing materials, on-demand manufacturing services, and a portfolio of end-to-end manufacturing software. Each solution is based on the expertise of the company’s application engineers who work with customers to transform manufacturing environments. 3D Systems’ solutions address a variety of advanced applications from prototyping to manufacturing in markets such as aerospace, automotive, medical, dental and consumer products. More information about the company can be found at www.3dsystems.com.
CollPlant is a regenerative and aesthetic medicine company that focuses on 3D bioprinting of tissues and organs as well as medical aesthetics. The company’s products are based on rhCollagen (recombinant human collagen), which is manufactured using CollPlant’s proprietary genetic engineering technology. These products address indications for the various areas of tissue repair, aesthetics and organ production and usher in a new era in regenerative and aesthetic medicine. CollPlant recently entered into a development and global commercialization agreement for skin and soft tissue fillers with Allergan, an AbbVie company, the world leader in the dermal filler market. Further information on CollPlant can be found at http://www.collplant.com
Safe Harbor for forward-looking statements
This press release may contain forward-looking statements. Forward-looking statements may include statements relating to the goals, plans and strategies of CollPlant and 3D Systems as well as statements other than historical facts that relate to activities, events or developments that CollPlant and 3D Systems intend to affect, respectively , projects, believes or expects that this will or can happen in the future. These statements are often accompanied by terms such as “believes”, “hopes”, “may”, “anticipates”, “should”, “intends”, “plans”, “will”, “expects”, “estimates”, “projects” , “positions”, “strategy” and similar expressions and are based on assumptions and estimates made in the light of management’s experience and perceptions of historical trends, current conditions, expected future developments and other factors deemed appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause the actual activities or results of CollPlant and 3D Systems to differ materially from those anticipated in any forward-looking statements, including, but not limited to the following: CollPlant’s history of material losses and the need for additional Fund raising capital and its inability to raise additional capital on acceptable terms or at all; Expectations of CollPlant and 3D Systems regarding the timing and cost of initiating clinical trials for tissues and organs based on the rhCollagen-based BioInk; the ability of CollPlant and 3D Systems or its business partners to achieve favorable preclinical and clinical trial results; regulatory actions in relation to rhCollagen-based BioInk, including, but not limited to, acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the rhCollagen-based BioInk and 3D Systems technologies from CollPlant; CollPlant’s ability to build sales and marketing capacity or to enter into agreements with third parties and its reliance on third party dealers and resellers; the ability of CollPlant and 3D Systems to establish and maintain strategic partnerships and other corporate collaborations; the reliance on CollPlant and 3D Systems on third parties to perform some aspects of product manufacturing; the scope of protection that CollPlant and 3D Systems are able to establish and maintain intellectual property rights and the ability of companies to conduct their business without infringing the intellectual property rights of others; the global global economic environment; the effects of competition and new technology; general market, political and economic conditions in the countries in which the companies operate; planned capital expenditures and liquidity; Changes in corporate strategy; as well as judicial and administrative proceedings. For more detailed information on the risks and uncertainties affecting CollPlant and 3D Systems, see the “Risk Factors” heading in CollPlant’s latest Annual Report on Form 20-F and 3D Systems’ latest Annual Report on Form 10-K and other periodic filings , which CollPlant and 3D Systems have filed with the SEC. The forward-looking statements contained in this press release are valid as of the date of this press release and reflect the current views of CollPlant and 3D Systems with respect to future events or revise forward-looking statements, whether as a result of new information, future events or otherwise.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2c40dd6e-f1d5-4ed3-8cb2-588c56a1e8d6